Logo
mobilemenu
close
CMN Live
CMN+
Home
Clinical Trials
Diseases
CRISPR&
CRISPR and Acute Myeloid Leukemia
CRISPR and Beta-Thalassemia
CRISPR and Cancer
CRISPR and Diabetes
CRISPR and Duchenne Muscular Dystrophy
CRISPR and Herpes Simplex Virus (HSV)
CRISPR and HIV
CRISPR and Sickle Cell Disease (SCD)
Companies
CRISPRMED
CRISPRMED24
CRISPRMED25
Events
CMN Jobs
Job Upload Form
Webinars
CMN Webinars On-demand - All
CMN Webinar - Disrupting the Care of Cardiovascular Disease With Single-Course Gene Editing Medicines
CMN Webinar - Taking the Guesswork Out of Drug Development: CRISPR-Select Validates Drug Targets and Drug Responders Early and Conclusively
CMN Webinar - Clinical-Grade gRNA for Genomic Medicines: Making Sense of the CRISPR Regulatory Landscape
CMN Webinar - Enhancing T Cell Function for Cancer immunotherapy With CRISPR
CMN Webinar - Engineering Approaches to Improve CRISPR Technologies
CMN Webinar - Development of CRISPR/Cas9-based Therapies against Alzheimer's Disease
CMN Webinar - Epigenomic Editing Ameliorates Detrimental Effects of Adolescent Alcohol Exposure
CMN Webinar - Gene Editing for Junctional Epidermolysis Bullosa
CMN Webinar - Multiplexed Genome Regulation In Vivo with Hyper-efficient Cas12a
CMN Webinar - The TCR Therapy Revival
CMN Webinar - Deliver CRISPR to the Brain - A New Treatment Strategy for Mucopolysaccharidoses
CMN Webinar - Controllable Genome Editing With Split-Engineered Base Editors
CMN Webinar - CRISPR-based Control of Insect-borne Diseases
CMN Webinar - CRISPR and MLD
CMN Webinar - CRISPR Off-Targets II
CMN Webinar - Rare Diseases and CRISPR
CMN Webinar - CRISPR On/Off Target
CMN Webinar - CRISPR Off-Targets
CMN Webinar - CRISPR Delivery Systems
CMN Webinar - Certainty After CRISPR
Advertising
WDC
About
search
Selfservice
|
Subscriberlogin
Logout
Prime Editors
Base Editors
Delivery
Safety
Off-target
Microbiome
CAR-T
TIL
Rare Diseases
Trials
Explainers
CMN Weekly
CARBON
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus, SLE, (NCT06373991)
Sponsors:
EdiGene Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT05988216)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT06255028)
Sponsors:
Century Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT06308978)
Sponsors:
Fate Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine
